GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...

Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade. Dr. Chowdhury began his presentation by emphasizing that muscle-invasive bladder cancer (MIBC) ...

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...

AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered ...

UBS downgraded enGene (ENGN) to Neutral from Buy with a price target of $7, down from $34, after assuming coverage of the name. enGene’s lead ...